How should TTOs choose between out licensing the IP, creating a spinoff or a contract-based R&D collaborations ?

What translation efforts don’t fit into this classical TTO model ?

How are these decisions taken ?

 

 

BioFIT is this year again the occasion to oppose point of views and learn from each other through an international panel !

 

On December 1st, at 2.30pm, in Van Gogh room, three TTOs, three continents, three different way to apprehend the matter will face each other in a panel, completed by a VC deeply involved in academic affairs:

  • Katja Rosenkranz, V-Bio Ventures, BE
  • Vivien Berlin, Harvard Tech Transfer Office, USA
  • Andrew Tinger, Imperial Innovations, UK
  • Doo Young Jung, Korea Rsearch Institute of Chemical Technology